HIV-free children whose mothers started taking anti-HIV medications while they were in the womb may be at higher risk for lower-than-average scores in one or more areas of development at age 5, according to a study supported by the National Institutes of Health.
NICHD issues News Releases and Media Advisories to the news media. Spotlight and Research Feature articles explain NICHD research findings and public health issues to the general public. An Item of Interest is a short announcement of relevant information, such as a notable staff change.
Science Update: Risk of developmental delays may be higher for HIV-free children whose mothers began antiretroviral treatment during pregnancy, NIH-funded study suggests
Selected NICHD Research Advances of 2022
Read about NICHD’s research findings and activities from 2022.
Director's Corner: Expanding Contraceptive Choices
A safe, highly effective, reversible method of male contraception would fill an important public health need. Additionally, multipurpose prevention technologies (MPTs)—products that prevent both pregnancy and sexually transmitted infections—would increase sexual and reproductive health options for both women and men. NICHD supports a broad range of contraceptive research, including efforts to develop male contraceptives and MPTs.
Spotlight: Scientific Advances from the Division of Intramural Research
The Division of Intramural Research provides fundamental knowledge about the nature and behavior of living systems through basic, clinical, and population-based research.
Science Update: Digital tool to increase youth HIV testing shows promise in NIH-funded study
Youth aged 13 to 24 years who were offered HIV testing by a digital health tool on a tablet computer were at least as likely to accept as those who were offered testing face-to-face, according to an NICHD-funded study.
Release: Youth with HIV less likely than adults to achieve viral suppression
Despite similar rates of enrollment into medical care, youth with HIV have much lower rates of viral suppression—reducing HIV to undetectable levels—compared to adults, according to an analysis funded by the National Institutes of Health.
Media Advisory: Many pregnant women with HIV prescribed treatment that does not meet federal guidelines
More than 20% of pregnant women beginning anti-HIV treatment were prescribed an antiretroviral treatment that did not meet federal guidelines for use during pregnancy, according to an analysis funded by the National Institutes of Health.
Media Advisory: Vesicles released by bacteria may reduce the spread of HIV in human tissue, NIH study suggests
Nano-sized vesicles released by certain bacteria that inhabit the vagina may protect against HIV infection, suggests a study of human cells and tissues by researchers at the National Institutes of Health and the University of Bologna, Italy. Known as extracellular vesicles, these bubble-like particles are produced by many kinds of cells and are thought to transport molecules from one cell to another.
Release: Exposure to HIV drug in the womb may increase risk of microcephaly, developmental delays in children
Children born to women on HIV therapy containing the drug efavirenz were 2 to 2.5 times more likely to have microcephaly, or small head size, compared to children born to women on regimens of other antiretroviral drugs, according to an analysis funded by the National Institutes of Health. The children with microcephaly also had a higher risk for developmental delays, compared to children with normal head size.
Media Advisory: Risk of neural tube defects slightly higher for babies of women on HIV therapy containing dolutegravir
Children born to women on HIV therapy containing the drug dolutegravir since conception have a slightly higher risk of neural tube defects, compared to children born to women on regimens of other antiretroviral drugs.
Science Update: Drug combination may lead to slight bone loss in young adolescent males, NIH-funded analysis suggests
Truvada, a drug combination that reduces the chances of HIV infection in high-risk people may result in small, yet persistent bone loss in younger adolescent males, suggests a study supported by the NICHD. The researchers added, however, that the protection against HIV offered by Truvada far outweighs any possible risks from bone loss.
Spotlight: Maternal Health Research Advances
NICHD was established more than 50 years ago to help understand maternal health and improve pregnancy outcomes. These selected advances highlight NICHD’s contributions to advancing the health and well-being of pregnant women, mothers, and families everywhere.
Item of Interest: NICHD Data and Specimen Hub (DASH) Releases New Biospecimen Request Functionality
Now available in DASH: Researchers can request access to NICHD biospecimens for secondary analyses.
Media Advisory: NICHD chronicles its major research advances of 2018
As 2018 winds down, a new slideshow highlights a selection of initiatives, therapies, and scientific advances supported by NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Spotlight: Selected NICHD Research Advances of 2018
In 2018, researchers funded by NICHD made significant progress in advancing the health and well-being of infants, children, teenagers, and adults across the United States and around the world.
Release: NIH funds study to prevent, treat HIV among adolescents in poor countries
The National Institutes of Health has awarded $7.5 million for an international research program to prevent and treat HIV infection among adolescents and young adults in seven African countries and Brazil.
Item of Interest: NIH extends study on HIV drug, dolutegravir, to evaluate potential safety concerns for pregnant women
The study seeks to determine if exposure poses a risk for neural tube defects.
Item of Interest: FDA approves PrEP therapy for adolescents at risk of HIV
The U.S. Food and Drug Administration (FDA) has approved an anti-HIV drug combination for use in at-risk adolescents. FDA’s decision was informed by an NICHD-supported study of adolescent males.
Drug combination reduces risk of HIV infection among teen males
A National Institutes of Health network study has confirmed that a combination of two drugs taken daily to reduce the chances of HIV infection among high-risk adults also works well and appears safe in males ages 15 to 17 years.
Release: Anti-HIV drug combination does not increase preterm birth risk, study suggests
A drug combination aimed at preventing transmission of HIV from a pregnant woman to her fetus likely does not increase the risk for preterm birth and early infant death, according to a re-analysis of two studies funded by the National Institutes of Health.